Stay updated on Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.

Latest updates to the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has undergone significant content changes, including the removal of detailed study descriptions and inclusion criteria for a clinical trial on non-small cell lung cancer, while adding a new revision number and a study identifier.SummaryDifference46%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4 and removed a date reference of March 25, 2025, while adding a new date of December 27, 2024.SummaryDifference0.2%
- Check37 days agoChange DetectedThe page has been updated to reflect a new revision version (v2.14.3) and a new results posting date of March 25, 2025, replacing the previous estimated dates and version. This indicates a significant update in the content's accuracy and reliability.SummaryDifference0.3%
- Check44 days agoChange DetectedThe web page has been updated to include new details about the dosing and treatment protocols for a clinical study involving Nintedanib, Nivolumab, and Ipilimumab, while removing outdated information regarding previous study phases and results.SummaryDifference7%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1.0%
Stay in the know with updates to Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.